Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Problems with Generics Pointed Out in 19/40 Studies
October 15, 2007
- Merck Serono Sets Out Focusing on Cancer, Infertility
October 15, 2007
- 3 Domestic Generic Firms to Hold IR Meeting in London
October 15, 2007
- Mylan Enters Market in Japan by Acquiring Merck's Generic Drug Business
October 15, 2007
- Public Opinions Invited on Documents Required for Applications for Generics
October 15, 2007
- Mitsubishi Tanabe Pharma Corp. Aims at Becoming Global Drug Discovery Company
October 15, 2007
- Kaken Completes PIIb Trial for KCB-1D as Drug to Regenerate Periodontal Tissue
October 15, 2007
- Taisho Licenses Psychiatric Drug Candidates to BrainCells
October 15, 2007
- Silodosin Was Found to Be Superior to Tamsulosin: Kissei
October 15, 2007
- EPS Ties Up with Medidata Solutions Regarding EDC Software
October 15, 2007
- First Gene Therapeutic to Regenerate Blood Vessels Expected in 2008
October 15, 2007
- VITAL-NET, KSK Enter into Comprehensive Business Alliance
October 15, 2007
- Physician-Initiated Trials Led by JMACCT Generating Results
October 15, 2007
- Council Recommends Improvements of Drug Trade Practices
October 15, 2007
- Guideline Issued on Multinational Cooperative Clinical Studies
October 15, 2007
- BUSINESS NEWS IN BRIEF
October 15, 2007
- Number of Documents Necessary for Clinical Trials Halved
October 15, 2007
- TOPICS／2007 JCA-Mauvernay Award Granted to 2 Japanese Scientists
October 15, 2007
- Korosho Proposes Higher Premiums for Pediatric and Orphan Drugs: Chuikyo
October 15, 2007
- R&D NEWS IN BRIEF
October 15, 2007
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…